Physician profile
Michael A Brown
NPI 1306874276
$12,895.37
in general payments reported to CMS, 2019-2025
42 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,441 · 2020: $1,849 · 2021: $2,653 · 2022: $1,929 · 2023: $1,943 · 2024: $1,829 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,023.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,325.44 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals Lp | $1,299.01 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $1,197.11 | 2019-2025 | |
| Lilly USA, LLC | $1,060.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,055.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $670.90 | 2019-2025 | Otezla, Repatha, Evenity |
| Novartis Pharmaceuticals Corporation | $647.35 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $516.02 | 2020-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $441.30 | 2019-2025 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $420.91 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $411.15 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $404.27 | 2021-2025 | |
| Allergan, INC. | $381.01 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $333.04 | 2019-2023 | Verquvo, Belsomra, Lagevrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $328.50 | 2019-2025 | Xifaxan |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.